Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.

Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).

Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).

"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg"